Trends in Renal-Cell Carcinoma Incidence and Mortality in the United States in the Last 2 Decades: A SEER-Based Study

Overview

Journal Clin Genitourin Cancer

Publisher Elsevier

Specialties Oncology
Urology

Date 2018 Nov 5

PMID 30391138

Citations 86

Authors

Anas M Saad

Mohamed M Gad

Muneer J Al-Husseini

Inas A Ruhban

Mohamad Bassam Sonbol

Thai H Ho

Affiliations

Soon will be listed here.

Abstract

Background: Renal-cell carcinoma (RCC) is one of the common malignancies in the United States. RCC incidence and mortality have been changing for many reasons. We performed a thorough investigation of incidence and mortality trends of RCC in the United States using the cell Surveillance, Epidemiology, and End Results (SEER) database.

Patients And Methods: The 13 SEER registries were accessed for RCC cases diagnosed between 1992 and 2015. Incidence and mortality were calculated by demographic and tumor characteristics. We calculated annual percentage changes of these rates. Rates were expressed as 100,000 person-years.

Results: A total of 104,584 RCC cases were reviewed, with 47,561 deaths. The overall incidence was 11.281 per 100,000 person-years. Incidence increased by 2.421% per year (95% confidence interval, 2.096, 2.747; P < .001) but later became stable since 2008. However, the incidence of clear-cell subtype continued to increase (1.449%; 95% confidence interval, 0.216, 2.697; P = .024). RCC overall mortality rates have been declining since 2001. However, mortality associated with distant RCC only started to decrease in 2012, with an annual percentage change of 18.270% (95% confidence interval, -28.775, -6.215; P = .006).

Conclusion: Despite an overall increase in the incidence of RCC, there has been a recent plateau in RCC incidence rates with a significant decrease in mortality.

Citing Articles

Incidence and survival patterns of clear cell renal cell carcinoma from 2000 to 2017: A SEER Database Analysis.

Zou S, Cui L, Pai P, Lu Y, Li X, Wang G J Cancer. 2025; 16(5):1591-1597.

PMID: 39991582 PMC: 11843228. DOI: 10.7150/jca.105713.

The genomic landscape of metastatic clear-cell renal cell carcinoma and its prognostic value: a comprehensive analysis of a large real-world clinico-genomic database.

Rizzo M, Pezzicoli G, Povero M, Pradelli L, Sicari E, Barbiero V ESMO Open. 2025; 10(3):104294.

PMID: 39965361 PMC: 11876921. DOI: 10.1016/j.esmoop.2025.104294.

Surgery lengthens survival for collecting duct carcinoma: analysis of hospital-based cancer registry data in Japan.

Kandori S, Suzuki S, Kojo K, Isoda B, Tanaka T, Nitta S BMC Cancer. 2025; 25(1):138.

PMID: 39849400 PMC: 11760089. DOI: 10.1186/s12885-025-13572-8.

PrimerX: A Bayesian Multistage Cohort Embedded Randomised Trial to Evaluate the Role of Deferred Local Therapy of the Primary Tumour in Combination with Immune Checkpoint Inhibitor-based First-line Therapy in Metastatic Renal Cell Carcinoma Patients.

Figaroa O, Zondervan P, Kessels R, Berkhof J, Aarts M, Hamberg P Eur Urol Open Sci. 2024; 70:28-35.

PMID: 39483517 PMC: 11525453. DOI: 10.1016/j.euros.2024.09.002.

Efficacy of immune checkpoint inhibitor combination therapy prior to nephrectomy in advanced renal cell carcinoma: A retrospective pilot study.

Kiyota S, Yoshida T, Nakamoto T, Jino E, Mishima T, Kinoshita H BJUI Compass. 2024; 5(10):957-960.

PMID: 39416752 PMC: 11479799. DOI: 10.1002/bco2.419.

References

Siddaiah M, Krishna S, McInnes M, Quon J, Shabana W, Papadatos D . Is Ultrasound Useful for Further Evaluation of Homogeneously Hyperattenuating Renal Lesions Detected on CT?. AJR Am J Roentgenol. 2017; 209(3):604-610. DOI: 10.2214/AJR.17.17814. View

Subramanian P, Haas N . Recent advances in localized RCC: A focus on VEGF and immuno-oncology therapies. Urol Oncol. 2017; 36(1):23-30. DOI: 10.1016/j.urolonc.2017.09.008. View

Oon S, Foley R, Quinn D, Quinlan D, Gibney R . Contrast-enhanced ultrasound of the kidney: a single-institution experience. Ir J Med Sci. 2017; 187(3):795-802. DOI: 10.1007/s11845-017-1725-6. View

Choueiri T, Halabi S, Sanford B, Hahn O, Michaelson M, Walsh M . Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial. J Clin Oncol. 2017; 35(6):591-597. PMC: 5455807. DOI: 10.1200/JCO.2016.70.7398. View

Siegel R, Miller K, Jemal A . Cancer statistics, 2018. CA Cancer J Clin. 2018; 68(1):7-30. DOI: 10.3322/caac.21442. View

Kim H, Fay M, Feuer E, Midthune D . Permutation tests for joinpoint regression with applications to cancer rates. Stat Med. 2000; 19(3):335-51. DOI: 10.1002/(sici)1097-0258(20000215)19:3<335::aid-sim336>3.0.co;2-z. View

Argani P, Lae M, Ballard E, Amin M, Manivel C, Hutchinson B . Translocation carcinomas of the kidney after chemotherapy in childhood. J Clin Oncol. 2006; 24(10):1529-34. DOI: 10.1200/JCO.2005.04.4693. View

Cumberbatch M, Rota M, Catto J, La Vecchia C . The Role of Tobacco Smoke in Bladder and Kidney Carcinogenesis: A Comparison of Exposures and Meta-analysis of Incidence and Mortality Risks. Eur Urol. 2015; 70(3):458-66. DOI: 10.1016/j.eururo.2015.06.042. View

Chow W, Dong L, Devesa S . Epidemiology and risk factors for kidney cancer. Nat Rev Urol. 2010; 7(5):245-57. PMC: 3012455. DOI: 10.1038/nrurol.2010.46. View

10.

Choi Y, Park B, Jeong B, Seo S, Jeon S, Choi H . Body mass index and survival in patients with renal cell carcinoma: a clinical-based cohort and meta-analysis. Int J Cancer. 2012; 132(3):625-34. DOI: 10.1002/ijc.27639. View

11.

Li P, Wong Y, Armstrong K, Haas N, Subedi P, Davis-Cerone M . Survival among patients with advanced renal cell carcinoma in the pretargeted versus targeted therapy eras. Cancer Med. 2015; 5(2):169-81. PMC: 4735783. DOI: 10.1002/cam4.574. View

12.

Bosetti C, Bertuccio P, Chatenoud L, Negri E, La Vecchia C, Levi F . Trends in mortality from urologic cancers in Europe, 1970-2008. Eur Urol. 2011; 60(1):1-15. DOI: 10.1016/j.eururo.2011.03.047. View

13.

Campbell S, Uzzo R, Allaf M, Bass E, Cadeddu J, Chang A . Renal Mass and Localized Renal Cancer: AUA Guideline. J Urol. 2017; 198(3):520-529. DOI: 10.1016/j.juro.2017.04.100. View

14.

Roos F, Steffens S, Junker K, Janssen M, Becker F, Wegener G . Survival advantage of partial over radical nephrectomy in patients presenting with localized renal cell carcinoma. BMC Cancer. 2014; 14:372. PMC: 4038042. DOI: 10.1186/1471-2407-14-372. View

15.

MacLennan S, Imamura M, Lapitan M, Omar M, Lam T, Hilvano-Cabungcal A . Systematic review of oncological outcomes following surgical management of localised renal cancer. Eur Urol. 2012; 61(5):972-93. DOI: 10.1016/j.eururo.2012.02.039. View

16.

Tannir N, Hammers H, Amin A . First-line vascular endothelial growth factor targeted therapy in renal cell carcinoma: priming the tumor microenvironment for immunotherapy. Curr Med Res Opin. 2018; 34(5):825-831. DOI: 10.1080/03007995.2018.1423960. View

17.

Cho E, Curhan G, Hankinson S, Kantoff P, Atkins M, Stampfer M . Prospective evaluation of analgesic use and risk of renal cell cancer. Arch Intern Med. 2011; 171(16):1487-93. PMC: 3691864. DOI: 10.1001/archinternmed.2011.356. View

18.

van Poppel H, Da Pozzo L, Albrecht W, Matveev V, Bono A, Borkowski A . A prospective, randomised EORTC intergroup phase 3 study comparing the oncologic outcome of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma. Eur Urol. 2010; 59(4):543-52. DOI: 10.1016/j.eururo.2010.12.013. View

19.

Zucchetto A, Dal Maso L, Tavani A, Montella M, Ramazzotti V, Talamini R . History of treated hypertension and diabetes mellitus and risk of renal cell cancer. Ann Oncol. 2006; 18(3):596-600. DOI: 10.1093/annonc/mdl438. View

20.

Maruvka Y, Tang M, Michor F . On the validity of using increases in 5-year survival rates to measure success in the fight against cancer. PLoS One. 2014; 9(7):e83100. PMC: 4108307. DOI: 10.1371/journal.pone.0083100. View